South Korea
· Delayed Price · Currency is KRW Korean Drug Statistics
Total Valuation
Korean Drug has a market cap or net worth of KRW 53.31 billion. The enterprise value is 34.39 billion.
| Market Cap | 53.31B |
| Enterprise Value | 34.39B |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Korean Drug has 10.91 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 10.91M |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.43% |
| Owned by Insiders (%) | 50.60% |
| Owned by Institutions (%) | n/a |
| Float | 5.39M |
Valuation Ratios
The trailing PE ratio is 17.57.
| PE Ratio | 17.57 |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | 13.87 |
| P/OCF Ratio | 10.95 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.57, with an EV/FCF ratio of 8.95.
| EV / Earnings | 11.48 |
| EV / Sales | 0.47 |
| EV / EBITDA | 5.57 |
| EV / EBIT | 8.38 |
| EV / FCF | 8.95 |
Financial Position
The company has a current ratio of 8.73, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.73 |
| Quick Ratio | 5.81 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.02 |
| Interest Coverage | 968.09 |
Financial Efficiency
Return on equity (ROE) is 3.86% and return on invested capital (ROIC) is 3.30%.
| Return on Equity (ROE) | 3.86% |
| Return on Assets (ROA) | 2.87% |
| Return on Invested Capital (ROIC) | 3.30% |
| Return on Capital Employed (ROCE) | 5.03% |
| Revenue Per Employee | 270.38M |
| Profits Per Employee | 11.09M |
| Employee Count | 270 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 2.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.70% in the last 52 weeks. The beta is 0.36, so Korean Drug's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -20.70% |
| 50-Day Moving Average | 4,760.90 |
| 200-Day Moving Average | 4,914.05 |
| Relative Strength Index (RSI) | 66.07 |
| Average Volume (20 Days) | 8,307 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Korean Drug had revenue of KRW 73.00 billion and earned 3.00 billion in profits. Earnings per share was 278.00.
| Revenue | 73.00B |
| Gross Profit | 34.40B |
| Operating Income | 4.10B |
| Pretax Income | 4.99B |
| Net Income | 3.00B |
| EBITDA | 6.17B |
| EBIT | 4.10B |
| Earnings Per Share (EPS) | 278.00 |
Balance Sheet
The company has 19.00 billion in cash and 80.97 million in debt, giving a net cash position of 18.92 billion or 1,733.75 per share.
| Cash & Cash Equivalents | 19.00B |
| Total Debt | 80.97M |
| Net Cash | 18.92B |
| Net Cash Per Share | 1,733.75 |
| Equity (Book Value) | 78.11B |
| Book Value Per Share | 7,270.45 |
| Working Capital | 55.72B |
Cash Flow
In the last 12 months, operating cash flow was 4.87 billion and capital expenditures -1.03 billion, giving a free cash flow of 3.84 billion.
| Operating Cash Flow | 4.87B |
| Capital Expenditures | -1.03B |
| Free Cash Flow | 3.84B |
| FCF Per Share | 352.08 |
Margins
Gross margin is 47.12%, with operating and profit margins of 5.62% and 4.10%.
| Gross Margin | 47.12% |
| Operating Margin | 5.62% |
| Pretax Margin | 6.84% |
| Profit Margin | 4.10% |
| EBITDA Margin | 8.46% |
| EBIT Margin | 5.62% |
| FCF Margin | 5.26% |
Dividends & Yields
This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 3.28%.
| Dividend Per Share | 160.00 |
| Dividend Yield | 3.28% |
| Dividend Growth (YoY) | 6.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 54.02% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 3.36% |
| Earnings Yield | 5.62% |
| FCF Yield | 7.21% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korean Drug has an Altman Z-Score of 6.34.
| Altman Z-Score | 6.34 |
| Piotroski F-Score | n/a |